Cargando…

Inpatient prescribing of dual antiplatelet therapy according to the guidelines: a prospective intervention study

BACKGROUND: In dual antiplatelet therapy (DAPT), low-dose acetylsalicylic acid is combined with a P2Y12 inhibitor. However, combining antithrombotic agents increases the risk of bleeding. Guidelines on DAPT recommend using this combination for a limited period of between three weeks and 30 months. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Moerlie, Ashwin R., van Uden, Renate C., Mantel-Teeuwisse, Aukje K., Van Den Bemt, Patricia, Becker, Matthijs L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centro de Investigaciones y Publicaciones Farmaceuticas 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7308913/
https://www.ncbi.nlm.nih.gov/pubmed/32587641
http://dx.doi.org/10.18549/PharmPract.2020.2.1803
_version_ 1783549102378713088
author Moerlie, Ashwin R.
van Uden, Renate C.
Mantel-Teeuwisse, Aukje K.
Van Den Bemt, Patricia
Becker, Matthijs L.
author_facet Moerlie, Ashwin R.
van Uden, Renate C.
Mantel-Teeuwisse, Aukje K.
Van Den Bemt, Patricia
Becker, Matthijs L.
author_sort Moerlie, Ashwin R.
collection PubMed
description BACKGROUND: In dual antiplatelet therapy (DAPT), low-dose acetylsalicylic acid is combined with a P2Y12 inhibitor. However, combining antithrombotic agents increases the risk of bleeding. Guidelines on DAPT recommend using this combination for a limited period of between three weeks and 30 months. This implies the risk of DAPT being erroneously continued after the intended stop date. OBJECTIVE: The primary objective of this study is to assess the proportion of hospitalized patients treated with DAPT whose treatment deviated erroneously and unintentionally from the guidelines. We also assessed risk factors and the effect of a pharmacist intervention. METHODS: All patients admitted to the Spaarne Gasthuis (Haarlem/ Hoofddorp, the Netherlands) who used DAPT between March 25 (th) , 2019, and June 14 (th) , 2019, were, in addition to receiving regular care, reviewed to assess whether their therapy was in line with the guidelines’ recommendation and whether deviations were unintended and erroneous. In the event of an unintended deviation, the pharmacist intervened by contacting the prescriber by phone and giving advice to adjust the antithrombotic therapy in line with the guideline. RESULTS: We included 411 patients, of whom 21 patients (5.1%) had a treatment that deviated from the guidelines. For 11 patients (2.7%), the deviation was unintended and erroneous. The major risk factor for erroneous deviation was the use of DAPT before hospital admission (OR 18.7; 95%CI 4.79–72.7). In patients who used DAPT before admission, 18 out of 58 (31.0%) had a deviation from the guidelines of whom 8 (13.8%) were erroneous. For these eight patients, the pharmacist contacted the prescriber, and in these cases the therapy was adjusted in line with the guidelines. CONCLUSIONS: Adherence to the guidelines recommending DAPT was high within the hospital. However, patients who used DAPT before hospital admission had a higher risk of erroneous prescription of DAPT. Intervention by a pharmacist increased adherence to guidelines and may reduce the number of preventable bleeding cases.
format Online
Article
Text
id pubmed-7308913
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Centro de Investigaciones y Publicaciones Farmaceuticas
record_format MEDLINE/PubMed
spelling pubmed-73089132020-06-24 Inpatient prescribing of dual antiplatelet therapy according to the guidelines: a prospective intervention study Moerlie, Ashwin R. van Uden, Renate C. Mantel-Teeuwisse, Aukje K. Van Den Bemt, Patricia Becker, Matthijs L. Pharm Pract (Granada) Original Research BACKGROUND: In dual antiplatelet therapy (DAPT), low-dose acetylsalicylic acid is combined with a P2Y12 inhibitor. However, combining antithrombotic agents increases the risk of bleeding. Guidelines on DAPT recommend using this combination for a limited period of between three weeks and 30 months. This implies the risk of DAPT being erroneously continued after the intended stop date. OBJECTIVE: The primary objective of this study is to assess the proportion of hospitalized patients treated with DAPT whose treatment deviated erroneously and unintentionally from the guidelines. We also assessed risk factors and the effect of a pharmacist intervention. METHODS: All patients admitted to the Spaarne Gasthuis (Haarlem/ Hoofddorp, the Netherlands) who used DAPT between March 25 (th) , 2019, and June 14 (th) , 2019, were, in addition to receiving regular care, reviewed to assess whether their therapy was in line with the guidelines’ recommendation and whether deviations were unintended and erroneous. In the event of an unintended deviation, the pharmacist intervened by contacting the prescriber by phone and giving advice to adjust the antithrombotic therapy in line with the guideline. RESULTS: We included 411 patients, of whom 21 patients (5.1%) had a treatment that deviated from the guidelines. For 11 patients (2.7%), the deviation was unintended and erroneous. The major risk factor for erroneous deviation was the use of DAPT before hospital admission (OR 18.7; 95%CI 4.79–72.7). In patients who used DAPT before admission, 18 out of 58 (31.0%) had a deviation from the guidelines of whom 8 (13.8%) were erroneous. For these eight patients, the pharmacist contacted the prescriber, and in these cases the therapy was adjusted in line with the guidelines. CONCLUSIONS: Adherence to the guidelines recommending DAPT was high within the hospital. However, patients who used DAPT before hospital admission had a higher risk of erroneous prescription of DAPT. Intervention by a pharmacist increased adherence to guidelines and may reduce the number of preventable bleeding cases. Centro de Investigaciones y Publicaciones Farmaceuticas 2020 2020-06-10 /pmc/articles/PMC7308913/ /pubmed/32587641 http://dx.doi.org/10.18549/PharmPract.2020.2.1803 Text en Copyright: © Pharmacy Practice and the Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY-NC-ND 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research
Moerlie, Ashwin R.
van Uden, Renate C.
Mantel-Teeuwisse, Aukje K.
Van Den Bemt, Patricia
Becker, Matthijs L.
Inpatient prescribing of dual antiplatelet therapy according to the guidelines: a prospective intervention study
title Inpatient prescribing of dual antiplatelet therapy according to the guidelines: a prospective intervention study
title_full Inpatient prescribing of dual antiplatelet therapy according to the guidelines: a prospective intervention study
title_fullStr Inpatient prescribing of dual antiplatelet therapy according to the guidelines: a prospective intervention study
title_full_unstemmed Inpatient prescribing of dual antiplatelet therapy according to the guidelines: a prospective intervention study
title_short Inpatient prescribing of dual antiplatelet therapy according to the guidelines: a prospective intervention study
title_sort inpatient prescribing of dual antiplatelet therapy according to the guidelines: a prospective intervention study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7308913/
https://www.ncbi.nlm.nih.gov/pubmed/32587641
http://dx.doi.org/10.18549/PharmPract.2020.2.1803
work_keys_str_mv AT moerlieashwinr inpatientprescribingofdualantiplatelettherapyaccordingtotheguidelinesaprospectiveinterventionstudy
AT vanudenrenatec inpatientprescribingofdualantiplatelettherapyaccordingtotheguidelinesaprospectiveinterventionstudy
AT mantelteeuwisseaukjek inpatientprescribingofdualantiplatelettherapyaccordingtotheguidelinesaprospectiveinterventionstudy
AT vandenbemtpatricia inpatientprescribingofdualantiplatelettherapyaccordingtotheguidelinesaprospectiveinterventionstudy
AT beckermatthijsl inpatientprescribingofdualantiplatelettherapyaccordingtotheguidelinesaprospectiveinterventionstudy